- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of recurrent clostridium difficile infection (CDI)
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Bezlotoxumab – July 2019
Bezlotoxumab: Solution concentrate for I.V. infusion 1000 mg in 40 mL; Zinplava®
Last updated
1 November 2019